Qube Research & Technologies LTD Blueprint Medicines Corp Transaction History
Qube Research & Technologies LTD
- $62.3 Billion
- Q2 2024
A detailed history of Qube Research & Technologies LTD transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Qube Research & Technologies LTD holds 132,048 shares of BPMC stock, worth $12 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
132,048
Previous 11,872
1012.26%
Holding current value
$12 Million
Previous $1.13 Million
1163.94%
% of portfolio
0.02%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding BPMC
# of Institutions
340Shares Held
62MCall Options Held
987KPut Options Held
578K-
Black Rock Inc. New York, NY6.65MShares$605 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.54MShares$595 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.87MShares$534 Million0.08% of portfolio
-
Wellington Management Group LLP Boston, MA3.24MShares$294 Million0.06% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.46MShares$224 Million8.22% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.43B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...